Abstract-Early diagnosis of dopa-responsive dystonia (DRD) and its delineation from other dystonic syndromes is of great relevance because DRD is an eminently treatable condition. The possible relevance of the phenylalanine loading test (Phe-L) in differentiating DRD from primary focal and generalized dystonia was investigated. A marked difference in the phenylalanine/tyrosine ratio between patients with DRD and patients with other types of dystonia was observed. This indicates that Phe-L may be helpful in the differential diagnosis of dystonias. NEUROLOGY 2003;60:700 -702 There is excellent and sustained improvement on simple oral drug treatment with the dopamine precursor substance L-dopa in patients with doparesponsive dystonia (DRD), unlike all other forms of dystonia. However, there is considerable phenotypic overlap between DRD and other dystonic syndromes.
There is excellent and sustained improvement on simple oral drug treatment with the dopamine precursor substance L-dopa in patients with doparesponsive dystonia (DRD), unlike all other forms of dystonia. However, there is considerable phenotypic overlap between DRD and other dystonic syndromes. 1 Thus, a diagnostic test that would reliably identify DRD and delineate patients with DRD from those with other dystonic syndromes would be of considerable clinical relevance to ensure early treatment of DRD while avoiding unnecessary L-dopa treatment in patients with other forms of dystonia.
In 1994, the GTP cyclohydrolase I gene (GCH-1) was isolated as the first causative gene for DRD and the first mutations in classic cases of DRD were identified. 2 However, sequence analysis of GCH-1 is not useful as a routine diagnostic procedure because mutations in GCH-1 can only be found in approximately half of all DRD cases. 3 Furthermore, unlike in the DYT1 gene torsinA, there is no common mutation. Rather, the mutations are spread over the entire coding sequence and the adjacent splice sites. Mutations outside the coding region might also be of some relevance and there may also be genetic heterogeneity in DRD. 1, 4, 5 Thus, mutation screening in suspected cases of DRD is time-consuming and does not reliably lead to confirmation of the diagnosis.
Outside the CNS, BH4 also acts as a cofactor for phenylalanine hydroxylase, which catalyzes the hydroxylation of phenylalanine to tyrosine in the liver. Autosomal recessively inherited, complete or nearcomplete BH4 deficiency presents in early infancy with hyperphenylalaninemia in addition to severe impairment of neurotransmitter synthesis. 6 An abnormal ratio of phenylalanine to tyrosine in the group analysis of the so-called phenylalanine loading test (Phe-L) compared to normal controls has previously been described in a group of patients with genetically proven DRD with classic phenotype from two large families, indicating that phenylalanine metabolism is also comprised in DRD. 7 However, information is lacking as to whether the Phe-L might be useful to differentiate DRD in an individual patient from other types of dystonia that overlap clinically with DRD, such as focal or generalized idiopathic torsion dystonia (F-ITD, G-ITD). The aim of this study was to investigate the possible relevance of the Phe-L in differentiating DRD from F-ITD or G-ITD. Furthermore, the previously reported protocol of the Phe-L involves repeated blood taking and measurements of phenylalanine and tyrosine at five time points (0, 1, 2, 4, and 6 hours). A reduced number of measurements would facilitate the introduction of the Phe-L into routine clinical practice and we therefore investigated whether single time point analysis might be sufficient.
Patients and methods.
Patients. In total, 30 patients were investigated. Ten patients had DRD, 10 had F-ITD, and 10 had G-ITD. The mean ages in the different patient groups were 35.3 years (SD 11.9 years) for the DRD patients, 59.8 years (SD 15.8 years) for F-ITD, and 35.8 years (SD 11.4 years) for G-ITD. The mean age at onset was 4.1 years (SD 3.1 years) for DRD, 48.1 years (SD 11.7 years) for F-ITD, and 24.3 years (SD 12.7 years) for G-ITD. The sex distribution was as follows: DRD: nine women, one man; F-ITD: nine women, one man; G-ITD: seven women, one man.
Controls. A total of 39 controls with a mean age of 29.8 years (SD 17.0 years) were included.
Mutations in the GCH-1 gene were detected in 7 of the 10 patients with DRD; none of the patients with F-ITD or G-ITD had the typical three-base pair deletion in the DYT1 gene torsinA (data not shown). 8 Secondary causes of dystonia such as Wilson disease or intracranial lesions were excluded in all patients. The diagnosis of DRD in the mutation-negative cases was based on a clear response to L-dopa. All other patients (F-ITD and G-ITD) included failed to show improvement on L-dopa treatment.
Oral phenylalanine load. The Phe-L was undertaken as previously described. 7 Blood samples were drawn into heparin tubes before the phenylalanine load and at 1, 2, and 4 hours postloading. Plasma was separated immediately, frozen on dry ice, and stored at Ϫ70°C. Phenylalanine and tyrosine were measured using standard high pressure liquid chromatography methods as previously described. 9 Data analysis. Values of phenylalanine, tyrosine, and the phenylalanine/tyrosine (Phe/Tyr) ratio were compared between patients with DRD and patients with F-ITD or G-ITD using the Mann-Whitney U test. 
Discussion.
We investigated the possible relevance of the Phe-L in the differential diagnosis of DRD. All patients with DRD were readily identified, reflecting a very high sensitivity of the Phe-L (100%). Furthermore, only 1 of the 20 patients with ITD tested had a Phe/Tyr ratio similar to patients with DRD 4 hours after the Phe-L, reflecting the very high specificity of this test (95%). This indicates that a possible introduction of the Phe-L into clinical practice may lead to a reliable identification of patients with DRD, but that unnecessary treatment with L-dopa cannot be avoided in all cases. There was no overlap between the Phe/Tyr ratios of any of the patients with DRD and the controls at 2 and 4 hours after the phenylalanine load. The patient with F-ITD with the unusually high Phe/Tyr ratio was followed up by lumbar puncture, genetic analysis of the phenylalanine hydroxylase gene (PAH), and an 8-week trial of L-dopa (125 mg three times a day). Biopterin, neopterin, and catecholamine metabolite values in the CSF were normal, no mutation was detected in the PAH, and her dystonia failed to improve on L-dopa treatment. Her abnormal Phe/Tyr ratio may reflect a heterozygote carrier state of one of the other BH4 or phenylalanine metabolizing enzymes; she should accordingly be classified as false positive.
Previously, the analysis of the Phe/Tyr ratio was undertaken 1, 2, 4, and 6 hours after the Phe-L. 7 However, our data indicate that single point analysis 4 hours after the Phe-L is sufficient. This would facilitate the introduction of the Phe-L into routine clinical practice. Our data also indicate that routine BH4 measurement after the Phe-L is not necessary to achieve high sensitivity and specificity. 10 This further facilitates clinical testing because BH4 measurement is technically demanding and is only undertaken in a limited number of laboratories. It should be noted that at least one other group has not found the Phe-L to be absolutely specific and sensitive for DRD. 10 If our results are confirmed by others, the introduction into routine clinical practice of the Phe-L as an easy to use, comparatively cheap, and quick diagnostic test for DRD might be helpful to ensure early treatment of patients with DRD.
